In particular, following a combination of inhibitors of two checkpoint molecules, programmed cell death 1 (PD1) and CTLA-4, an objective response rate of over 50% was seen in melanoma, although at the cost of significant side effects, most notably autoimmune diseases [8]. This evidence concerns the gene PDCD1 and melanoma.